Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02286167 : Glioma Modified Atkins-based Diet in Patients With Glioblastoma
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

1. Patients must have a clinical and histopathologic diagnosis of GBM, have completed
>80% of prescribed concurrent radiation therapy and adjuvant temozolomide without
CTCEA grade 3 or 4 toxicity, and be greater than 7 months from the time of completion
of concurrent chemoradiotherapy.

2. Karnofsky performance status >/= 60.

3. Patients must be at least 18 years of age.

4. Patients must be eligible to undergo a ketogenic or Atkins based diet according to
baseline body mass index (BMI, see exclusion criteria), comorbid medical conditions
(see exclusion criteria), and baseline laboratory assessment (see exclusion criteria).

5. Patients must be of appropriate mental capacities with sufficient social support so as
to be able to complete required study activities (i.e. diet record, etc) and able to
provide written informed consent.

Exclusion Criteria:

1. Patients with a history of a metabolic disorder including documented defect in urea
metabolism (including documented history of gout), carnitine deficiency (primary
carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine
translocase deficiency), fatty acid metabolism, beta-oxidation defects, pyruvate
carboxylase deficiency, mitochondrial function, porphyria, or nephrolithiasis.

2. Severe acute infection.

3. BMI > 35.0 or BMI < 20.0.

4. Active bowel obstruction, ileus, or active or remote pancreatitis.

5. Clinically significant heart failure (NYHA >2), recent myocardial infarction, or
symptomatic atrial fibrillation.

6. Clinically significant renal disease (creatinine >2.0 mg/dL, urea >100 mg/dL).

7. Clinically significant hepatic dysfunction (alanine or aspartate aminotransferase >7
times the upper limit of normal).

8. Patients with insulin-dependent diabetes mellitus.

9. Conditions that may increase the risk of the diet or significantly reduce compliance
(i.e. cognitive impairment, frank dementia, etc).

10. Other concurrent experimental therapies.

11. Milk allergy.

12. Treatment with the modified Atkins diet (MAD) for any cause within the 9 months prior
to study enrollment

13. Patient inability to complete baseline screening 3-day diet record.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02286167      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740